AUTL

MKT CAP:$383M

Autolus Therapeutics plc

Market Cap

$383M

Healthcare·Biotechnology·🇬🇧 United Kingdom·NASDAQ

Healthcare·Biotechnology·🇬🇧·NASDAQ

Stock Price

$1.55-$0.32 (-17.11%)

Apr 21, 2026

Company Details

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell i...

CEO

Christian Martin Itin

IPO Date

Jun 22, 2018

Website

www.autolus.com

Key Metrics TTM

Revenue

$75M

+644.6% YoY

Net Income

-$287M

EPS (Diluted)

-$1.08

Free Cash Flow

-$307M

Revenue / Share

$0.28

Gross Margin

-27.8%

Operating Margin

-358.9%

Net Margin

-381.4%

FCF Margin

-407.9%

P/S

5.1x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 27, 2026

$76MEPS -$1.08

Q4 2025

Mar 27, 2026

$24M+83534.2%EPS -$0.34

Q3 2025

Nov 12, 2025

$21MEPS -$0.30

Q2 2025

Aug 12, 2025

$21MEPS -$0.18

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$2M	-$42M
Q2 22	$0	$0	-$46M
Q3 22	$2M	-$35M	-$81M
Q4 22	$4M	$2M	-$30M
Q1 23	$1M	-$607.0K	-$35M
Q2 23	$0	$0	-$44M
Q3 23	$406.0K	-$1M	-$44M
Q4 23	$0	-$2M	-$41M
Q1 24	$10M	$8M	-$39M
Q2 24	$0	$0	-$59M
Q3 24	$0	-$1M	-$69M
Q4 24	$29.0K	-$138M	-$241M
Q1 25	$9M	-$9M	-$65M
Q2 25	$21M	-$4M	-$61M
Q3 25	$21M	-$7M	-$72M
Q4 25	$24M	-$1M	-$72M

Valuation

Quarter	P/S	P/E
Q1 22	184.4x	—
Q2 22	607.7x	—
Q3 22	100.2x	—
Q4 22	50.5x	—
Q1 23	45.1x	—
Q2 23	59.0x	—
Q3 23	68.7x	—
Q4 23	860.9x	—
Q1 24	143.9x	—
Q2 24	88.0x	—
Q3 24	95.7x	—
Q4 24	58.1x	—
Q1 25	45.8x	—
Q2 25	20.3x	—
Q3 25	8.3x	—
Q4 25	6.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$35M	-$36M
Q2 22	-$31M	-$33M
Q3 22	-$32M	-$39M
Q4 22	-$15M	-$15M
Q1 23	-$42M	-$46M
Q2 23	-$38M	-$43M
Q3 23	-$40M	-$42M
Q4 23	-$25M	-$26M
Q1 24	-$41M	-$41M
Q2 24	-$51M	-$52M
Q3 24	-$77M	-$86M
Q4 24	-$38M	-$62M
Q1 25	-$76M	-$84M
Q2 25	-$73M	-$80M
Q3 25	-$68M	-$52M
Q4 25	-$67M	-$91M

Capital Expenditures

Quarter	CapEx
Q1 22	$771.0K
Q2 22	$3M
Q3 22	$7M
Q4 22	$633.0K
Q1 23	$4M
Q2 23	$4M
Q3 23	$1M
Q4 23	$1M
Q1 24	$533.0K
Q2 24	$841.0K
Q3 24	$10M
Q4 24	$24M
Q1 25	$8M
Q2 25	$7M
Q3 25	$16M
Q4 25	$24M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-100.0%	-40.2%
Q2 22	-100.0%	-35.0%
Q3 22	+903.8%	+14.6%
Q4 22	+2025.0%	-60.8%
Q1 23	—	-12.6%
Q2 23	—	-4.6%
Q3 23	-82.9%	-46.8%
Q4 23	-100.0%	+19.8%
Q1 24	+681.0%	+33.2%
Q2 24	—	+32.9%
Q3 24	-100.0%	+54.9%
Q4 24	—	+490.6%
Q1 25	-11.0%	+51.9%
Q2 25	—	+39.4%
Q3 25	—	+34.8%
Q4 25	+83534.2%	-60.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$3M	—
Q3 22	$3M	140.9%
Q4 22	$3M	89.3%
Q1 23	$2M	186.4%
Q2 23	$3M	—
Q3 23	$3M	704.4%
Q4 23	$3M	—
Q1 24	$2M	22.6%
Q2 24	$3M	—
Q3 24	$4M	—
Q4 24	$6M	21493.1%
Q1 25	$3M	31.9%
Q2 25	$4M	20.5%
Q3 25	$4M	18.1%
Q4 25	$3M	14.2%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$34M	—	$6M
Q2 22	$38M	$8M	—
Q3 22	$38M	$8M	—
Q4 22	$27M	—	$6M
Q1 23	$27M	—	$7M
Q2 23	$33M	$11M	—
Q3 23	$32M	$11M	—
Q4 23	$25M	—	$14M
Q1 24	$31M	$18M	—
Q2 24	$37M	$22M	—
Q3 24	$40M	$27M	—
Q4 24	$51M	$67M	—
Q1 25	$27M	$30M	—
Q2 25	$27M	$30M	—
Q3 25	$28M	$36M	—
Q4 25	$36M	—	$36M

Revenue Segments

Quarter	License	Product
Q1 24	$10M	—
Q1 25	—	$9M
Q2 25	—	$21M
Q3 25	$50.0K	$21M
Q4 25	$1M	$23M

Revenue by Geography

Quarter	Germany	United States
Q1 24	$10M	—
Q1 25	—	$9M
Q2 25	—	$21M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$269M	$0	$269M
Q2 22	$216M	$0	$216M
Q3 22	$163M	$0	$163M
Q4 22	$382M	$0	$382M
Q1 23	$343M	$0	$343M
Q2 23	$308M	$0	$308M
Q3 23	$257M	$0	$257M
Q4 23	$240M	$0	$240M
Q1 24	$760M	$0	$760M
Q2 24	$707M	$0	$707M
Q3 24	$657M	$0	$657M
Q4 24	$227M	$361M	$588M
Q1 25	$96M	$421M	$517M
Q2 25	$124M	$330M	$454M
Q3 25	$86M	$281M	$367M
Q4 25	$104M	$197M	$301M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	91M	+24.7%	+45.6%
Q2 22	91M	+0.0%	+28.4%
Q3 22	91M	+0.3%	+25.2%
Q4 22	117M	+28.4%	+60.7%
Q1 23	174M	+48.3%	+91.2%
Q2 23	174M	+0.0%	+91.2%
Q3 23	174M	+0.1%	+90.7%
Q4 23	174M	+0.0%	+48.5%
Q1 24	222M	+27.7%	+27.8%
Q2 24	266M	+19.7%	+53.0%
Q3 24	266M	+0.0%	+52.9%
Q4 24	266M	+0.0%	+52.9%
Q1 25	266M	+0.0%	+19.8%
Q2 25	266M	+0.0%	+0.0%
Q3 25	266M	+0.0%	+0.0%
Q4 25	266M	+0.0%	+0.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	327
Q2 22	$0	327
Q3 22	$7.2K	327
Q4 22	$9.5K	404
Q1 23	$3.2K	404
Q2 23	$0	404
Q3 23	$1.0K	404
Q4 23	$0	471
Q1 24	$21.4K	471
Q2 24	$0	471
Q3 24	$0	471
Q4 24	$45	647
Q1 25	$13.9K	647
Q2 25	$32.3K	647
Q3 25	$32.8K	647
Q4 25	$32.2K	754

Revenue / Employee